ATE536355T1 - 3,3-spiroindolinionderivate als antikrebsmittel - Google Patents

3,3-spiroindolinionderivate als antikrebsmittel

Info

Publication number
ATE536355T1
ATE536355T1 AT08750071T AT08750071T ATE536355T1 AT E536355 T1 ATE536355 T1 AT E536355T1 AT 08750071 T AT08750071 T AT 08750071T AT 08750071 T AT08750071 T AT 08750071T AT E536355 T1 ATE536355 T1 AT E536355T1
Authority
AT
Austria
Prior art keywords
spiroindolinion
derivatives
anticancer agents
anticancer
agents
Prior art date
Application number
AT08750071T
Other languages
English (en)
Inventor
Jin-Jun Liu
Jefferson Wright Tilley
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE536355T1 publication Critical patent/ATE536355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT08750071T 2007-05-17 2008-05-06 3,3-spiroindolinionderivate als antikrebsmittel ATE536355T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93849407P 2007-05-17 2007-05-17
PCT/EP2008/055516 WO2008141917A1 (en) 2007-05-17 2008-05-06 3,3-spiroindolinone derivatives

Publications (1)

Publication Number Publication Date
ATE536355T1 true ATE536355T1 (de) 2011-12-15

Family

ID=39645551

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08750071T ATE536355T1 (de) 2007-05-17 2008-05-06 3,3-spiroindolinionderivate als antikrebsmittel

Country Status (16)

Country Link
US (1) US7553833B2 (de)
EP (1) EP2158205B1 (de)
JP (1) JP2010527340A (de)
KR (1) KR101162518B1 (de)
CN (1) CN101679446B (de)
AR (1) AR066583A1 (de)
AT (1) ATE536355T1 (de)
AU (1) AU2008253154A1 (de)
BR (1) BRPI0811718A2 (de)
CA (1) CA2686675A1 (de)
ES (1) ES2377245T3 (de)
IL (1) IL201973A0 (de)
MX (1) MX2009012345A (de)
PE (1) PE20090279A1 (de)
TW (1) TW200906832A (de)
WO (1) WO2008141917A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
US20100190814A1 (en) * 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) * 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) * 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
TWI535723B (zh) 2010-11-12 2016-06-01 密西根大學董事會 螺－吲哚酮ｍｄｍ２拮抗劑
RU2612534C2 (ru) 2011-03-10 2017-03-09 Дайити Санкио Компани, Лимитед Диспиропирролидиновые производные
SG194873A1 (en) 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
CN103992334A (zh) * 2014-05-29 2014-08-20 中国人民解放军第二军医大学 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
HRP20191414T1 (hr) 2014-08-21 2019-11-01 Boehringer Ingelheim Int Novi spojevi i derivati spiro[3h-indol-3,2'-pirolidin]-2(1h)-ona kao mdm1-p53-inhibitori
EP3260119B1 (de) 2015-02-20 2023-11-15 Daiichi Sankyo Company, Limited Kombinationsverfahren zur behandlung von krebs
CN105541716B (zh) 2015-03-26 2024-02-23 Ａｇｃ株式会社 吡唑衍生物的制造方法
TWI697329B (zh) 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
HUE054985T2 (hu) 2015-10-09 2021-11-29 Boehringer Ingelheim Int Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
CN113788818A (zh) 2016-04-06 2021-12-14 密执安大学评议会 Mdm2蛋白质降解剂
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CA3040840A1 (en) 2016-10-17 2018-04-26 Daiichi Sankyo Company, Limited Combined use of mdm2 inhibitor and dna methyltransferase inhibitor for cancer treatment
CN107337638A (zh) * 2017-08-14 2017-11-10 侯茜茜 一种吡啶甲酸类食品添加剂的高效合成方法
SG11202103282YA (en) 2018-10-08 2021-04-29 Univ Michigan Regents Small molecule mdm2 protein degraders
MX2022011602A (es) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN116496281B (zh) * 2022-12-30 2025-05-13 重庆文理学院 一种苯并氮卓螺二氢吲哚化合物及其合成方法与应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098212B (en) * 1981-05-12 1984-11-14 Ici Plc Process for preparing 1'-substituted-spiro(imidazolidine)-4,3'-indoline-2,2',5-triones
EP0947511A1 (de) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Phenoxy-Essigsäurederivate und Phenoxymetyl-Tetrazolderivate mit antitumoraler Wirkung
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
US20070213341A1 (en) * 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives

Also Published As

Publication number Publication date
CN101679446B (zh) 2012-06-27
CA2686675A1 (en) 2008-11-27
AU2008253154A1 (en) 2008-11-27
EP2158205B1 (de) 2011-12-07
US7553833B2 (en) 2009-06-30
KR20090130312A (ko) 2009-12-22
US20080287421A1 (en) 2008-11-20
CN101679446A (zh) 2010-03-24
BRPI0811718A2 (pt) 2014-11-18
JP2010527340A (ja) 2010-08-12
TW200906832A (en) 2009-02-16
PE20090279A1 (es) 2009-04-02
AR066583A1 (es) 2009-09-02
EP2158205A1 (de) 2010-03-03
MX2009012345A (es) 2009-12-01
IL201973A0 (en) 2010-06-16
ES2377245T3 (es) 2012-03-23
KR101162518B1 (ko) 2012-07-09
WO2008141917A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
ATE536355T1 (de) 3,3-spiroindolinionderivate als antikrebsmittel
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
LT3492069T (lt) Farmacinės kompozicijos, apimančios geležies oksihidroksidą
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
ATE540040T1 (de) Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
BRPI1006113A2 (pt) "derivado de piridina".
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BRPI0810646A2 (pt) " compostos farmacêuticos ".
EP2291078A4 (de) Oxazolbenzimidazolderivate
BRPI1008899A2 (pt) derivados 3,3´-espiroindolinona como agentes anticâncer
BRPI0716046A2 (pt) composiÇÕes de nanopartÍcula.
EP2279532A4 (de) Oxazolbenzimidazolderivate
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
BRPI0923048A2 (pt) "composto de aminopirazol".
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
EP2365820A4 (de) Endothel-simulierende nanomatrix
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI0816679A2 (pt) Derivados de ftalazinona.